As of April 26, 2023, roughly 367 million Pfizer-BioNTech COVID-19 vaccine doses had been administered in the United States. This statistic shows the number of COVID-19 vaccinations administered in the United States as of April 26, 2023, by manufacturer.

As of March 9, 2021, there were pre-purchase agreements for over three billion doses of AstraZeneca/Oxford's vaccine. This vaccine is by far the most sought after COVID-19 vaccine, especially due to its ability to be stored at normal refrigerator temperatures, while other vaccines might need ultra cold storage. Although still in phase III of clinical trials and without approval, Novavax's vaccine is the one with the second highest number of orders worldwide.

Global COVID-19 vaccine contracts At the same time, India had managed to secure around 2.2 billion COVID-19 vaccines doses, followed by the European Union which had signed pre-purchase agreements to secure nearly 1.84 billion doses of COVID-19 vaccines, while the United States already secured around 1.21 billion doses. AstraZeneca/Oxford's vaccine accounted for one billion doses of all vaccines secured by India, while also accounting for 300 million doses of all vaccines secured by the EU and the U.S., respectively.

Forecasted sales of COVID-19 vaccines As of November 2021, Comirnaty by BioNTech/Pfizer was the leading COVID-19 vaccine by forecasted sales revenue. It was expected to make around 36 billion U.S. dollars in sales revenue in 2021, followed by 29 billion dollars in 2022. Meanwhile, Spikevax by Moderna was projected to make 18 billion and 22 billion U.S. dollars in 2021 and 2022, respectively. Vaxzevria by AstraZeneca was forecasted to make 1.7 billion U.S. dollars in sales, followed by an additional 1.9 billion dollars by 2022. In contrast to most other biopharmaceutical companies, AstraZeneca had announced to sell its vaccine at almost net cost price.

CDC COVID-19 Vaccine Tracker

Cumulative and Daily Counts of COVID-19 Vaccine Doses in the United States

By Nicky Forster [source]

About this dataset

The dataset contains data points such as the cumulative count of people who have received at least one dose of the vaccine, new doses administered on a specific date, cumulative count of doses distributed in the country, percentage of population that has completed the full vaccine series, cumulative count of Pfizer and Moderna vaccine doses administered in each state, seven-day rolling averages for new doses administered and distributed, among others.

It also provides insights into the vaccination status at both national and state levels. The dataset includes information on the percentage of population that has received at least one dose of the vaccine, percentage of population that has completed the full vaccine series, cumulative counts per 100k population for both distributed and administered doses.

Additionally, it presents data specific to each state, including their abbreviation and name. It outlines details such as cumulative counts per 100k population for both distributed and administered doses in each state. Furthermore, it indicates if there were instances where corrections resulted in single-day negative counts.

The dataset is compiled from daily snapshots obtained from CDC's COVID Data Tracker. Please note that there may be reporting delays by healthcare providers up to 72 hours after administering a dose.

This comprehensive dataset serves various purposes including tracking vaccination progress over time across different locations within the United States. It can be used by researchers, policymakers or anyone interested in analyzing trends related to COVID-19 vaccination efforts at both national and state levels

How to use the dataset

• Familiarize Yourself with the Columns: Take a look at the available columns in this dataset to understand what information is included. These columns provide details such as state abbreviations, state names, dates of data snapshots, cumulative counts of doses distributed and administered, people who have received at least one dose or completed the vaccine series, percentages of population coverage, manufacturer-specific data, and seven-day rolling averages.

• Explore Cumulative Counts: The dataset includes cumulative counts that show the total number of doses distributed or administered over time. You can analyze these numbers to track trends in vaccination progress in different states or regions.

• Analyze Daily Counts: The dataset also provides daily counts of new vaccine doses distributed and administered on specific dates. By examining these numbers, you can gain insights into vaccination rates on a day-to-day basis.

• Study Population Coverage Metrics: Metrics such as pct_population_received_at_least_one_dose and pct_population_series_complete give you an understanding of how much of each state's population has received at least one dose or completed their vaccine series respectively.

• Utilize Manufacturer Data: The columns related to Pfizer and Moderna provide information about the number of doses administered for each manufacturer separately. By analyzing this data, you can compare vaccination rates between different vaccines.

• Consider Rolling Averages: The seven-day rolling average columns allow you to smooth out fluctuations in daily counts by calculating an average over a week's time window. This can help identify long-term trends more accurately.

• Compare States: You can compare vaccination progress between different states by filtering the dataset based on state names or abbreviations. This way, you can observe variations in distribution and administration rates among different regions.

• Visualize the Data: Creating charts and graphs will help you visualize the data more effectively. Plotting trends over time or comparing different metrics for various states can provide powerful visual representations of vaccination progress.

• Stay Informed: Keep in mind that this dataset is continuously updated as new data becomes available. Make sure to check for any updates or refreshed datasets to obtain the most recent information on COVID-19 vaccine distributions and administrations

Research Ideas

• Vaccination Analysis: This dataset can be used to analyze the progress of COVID-19 vaccinations in the United States. By examining the cumulative counts of doses distributed and administered, as well as the number of people who have received at least one dose or completed the vaccine series, researchers and policymakers can assess how effectively vaccines are being rolled out and monitor...

As of March 2023, approximately 48.9 million doses of Pfizer COVID-19 vaccine had been administered in Thailand. Other major vaccines included AstraZeneca with around 48.7 million doses administered, and Sinovac with around 26.6 million doses administered in the country.

NOTE: This dataset replaces a previous one. Please see below. Chicago residents who are up to date with COVID-19 vaccines by ZIP Code, based on the reported home address and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). “Up to date” refers to individuals who meet the CDC’s updated COVID-19 vaccination criteria based on their age and prior vaccination history. For surveillance purposes, up to date is defined based on the following criteria: People ages 5 years and older: · Are up to date when they receive 1+ doses of a COVID-19 vaccine during the current season. Children ages 6 months to 4 years: · Children who have received at least two prior COVID-19 vaccine doses are up to date when they receive one additional dose of COVID-19 vaccine during the current season, regardless of vaccine product. · Children who have received only one prior COVID-19 vaccine dose are up to date when they receive one additional dose of the current season's Moderna COVID-19 vaccine or two additional doses of the current season's Pfizer-BioNTech COVID-19 vaccine. · Children who have never received a COVID-19 vaccination are up to date when they receive either two doses of the current season's Moderna vaccine or three doses of the current season's Pfizer-BioNTech vaccine. This dataset takes the place of a previous dataset, which covers doses administered from December 15, 2020 through September 13, 2023 and is marked as historical: - https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccinations-by-ZIP-Code/553k-3xzc. Data Notes: Weekly cumulative totals of people up to date are shown for each combination ZIP Code and age group. Note there are rows where age group is "All ages" so care should be taken when summing rows. Coverage percentages are calculated based on the cumulative number of people in each ZIP Code and age group who are considered up to date as of the week ending date divided by the estimated number of people in that subgroup. Population counts are obtained from the 2020 U.S. Decennial Census. For ZIP Codes mostly outside Chicago, coverage percentages are not calculated reliable Chicago-only population counts are not available. Actual counts may exceed population estimates and lead to coverage estimates that are greater than 100%, especially in smaller ZIP Codes with smaller populations. Additionally, the medical provider may report a work address or incorrect home address for the person receiving the vaccination, which may lead to over- or underestimation of vaccination coverage by geography. All coverage percentages are capped at 99%. Weekly cumulative counts and coverage percentages are reported from the week ending Saturday, September 16, 2023 onward through the Saturday prior to the dataset being updated. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. The Chicago Department of Public Health uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Individuals may receive vaccinations that are not recorded in the Illinois immunization registry, I-CARE, such as those administered in another state, causing underestimation of the number individuals who are up to date. Inconsistencies in records of separate doses administered to the same person, such as slight variations in dates of birth, can result in duplicate records for a person and underestimate the number of people who are up to date. For all datasets related to COVID-19, please

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

NOTE: This dataset has been retired and marked as historical-only. The recommended dataset to use in its place is https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Coverage-ZIP-Code/2ani-ic5x. NOTE, 3/30/2023: We have added columns for bivalent (updated) doses to this dataset. We have also added age group columns for 0-17 and 18-64 and stopped updating the 5+ and 12+ columns, although previously published values remain for those columns. COVID-19 vaccinations administered to Chicago residents based on the home ZIP Code of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). The ZIP Code where a person lives is not necessarily the same ZIP Code where the vaccine was administered. Definitions: ·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine. ·People with a completed vaccine series: Number of people who have completed a primary COVID-19 vaccine series. Requirements vary depending on age and type of primary vaccine series received. ·People with a bivalent dose: Number of people who received a bivalent (updated) dose of vaccine. Updated, bivalent doses became available in Fall 2022 and were created with the original strain of COVID-19 and newer Omicron variant strains. ·Total doses administered: Number of all COVID-19 vaccine doses administered. Data Notes: Daily counts are shown for the total number of doses administered, number of people with at least one vaccine dose, number of people who have a completed vaccine series, and number of people who have received a bivalent dose. Cumulative totals for each measure as of that date are also provided. Vaccinations are counted based on the day the vaccine was administered. Coverage percentages are calculated based on cumulative number of people who have received at least one vaccine dose, cumulative number of people who have a completed vaccine series, and cumulative number of people who have received a bivalent dose in each ZIP Code. Population counts are from the U.S. Census Bureau American Community Survey 2015-2019 5-year estimates and can be seen in the ZIP Code, 2019 rows of the Chicago Population Counts dataset (https://data.cityofchicago.org/d/85cm-7uqa). Actual counts may exceed population estimates and lead to >100% coverage, especially in areas with small population sizes. Additionally, the medical provider may report a work address or incorrect home address for the person receiving the vaccination which may lead to over or under estimates of vaccination coverage by geography.  All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19. Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau American Community Survey

The time series of vaccines administered for coronavirus vaccination, divided by manufacturer, dose number (1, 2, 3, 4+) and federal states.

State-by-state data on United States COVID-19 vaccinations data

Acknowledgement and License

All data are produced by Our World in Data are completely open access under the Creative Commons BY license. You have the permission to use, distribute, and reproduce these in any medium, provided the source and authors are credited. In the case of our vaccination dataset, please give the following citation:

Mathieu, E., Ritchie, H., Ortiz-Ospina, E. et al. A global database of COVID-19 vaccinations. Nat Hum Behav (2021). https://doi.org/10.1038/s41562-021-01122-8

Data Set Column Details

location : name of the state or federal entity. date: date of the observation. total vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again. total vaccinations per hundred: total vaccinations per 100 people in the total population of the state. daily vaccinations raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily vaccinations instead. daily vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here. daily vaccinations per million: daily vaccinations per 1,000,000 people in the total population of the state. people vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same. people vaccinated per hundred: people vaccinated per 100 people in the total population of the state. people fully vaccinated: total number of people who received all doses prescribed by the initial vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1. people fully vaccinated per hundred: people fully vaccinated per 100 people in the total population of the state. total distributed: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System. total distributed per hundred: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System per 100 people in the total population of the state. share doses used: share of vaccination doses administered among those recorded as shipped in CDC's Vaccine Tracking System. total boosters: total number of COVID-19 vaccination booster doses administered (doses administered beyond the number prescribed by the initial vaccination protocol) total boosters per hundred: total boosters per 100 people in the total population.

Time Span

20th Dec 2020 to 28th Dec 2022

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in vacc

Content

The data presented in the Vaccine Tracker are submitted by European Union/European Economic Area (EU/EEA) countries to ECDC through The European Surveillance System (TESSy) twice a week (Tuesdays and Fridays). EU/EEA countries report aggregated data on the number of vaccine doses distributed by manufacturers to the country, the number of first, second and unspecified doses administered in the adult population (18+) overall, by age group and in specific target groups, such as healthcare workers (HCW) and in residents in long-term care facilities (LTCF). Doses are also reported by vaccine product. The downloadable data files contain the data on the COVID-19 vaccine rollout mentioned above and each row contains the corresponding data for a certain week and country. The file is updated daily. Data are subject to retrospective corrections; corrected datasets are released as soon as processing of updated national data has been completed. You may use the data in line with ECDC’s copyright policy.

• YearWeekISO: Date when the vaccine was received/administered. Only weeks are allowed (e.g. “2021-W01”). [yyyy-Www]
• ReportingCountry: ISO 3166-1-alpha-2 two-letter code
• Denominator: Population denominators for target groups (total population and agespecific population denominators do not need to be reported and will be obtained from Eurostat/UN). Denominators only need to be reported for TargetGroup = “HCW” and TargetGroup = “LTCF”. They should be reported every week for these target groups. [Numeric]
• NumberDosesReceived: Number of vaccine doses distributed by the manufacturers to the country during the reporting week. [Numeric]
• FirstDose: Number of first dose vaccine administered to individuals during the reporting week. [Numeric]
• FirstDoseRefused: Number of individuals refusing the first vaccine dose.[Numeric]
• SecondDose: Number of second dose vaccine administered to individuals during the reporting week.[Numeric]
• UnknownDose: Number of doses administered during the reporting week where the type of dose was not specified (i.e. it is not known whether it was a first or second dose).[Numeric]
• Region: As a minimum data should be reported at national level (Region = country code). Country/NUTS1 or 2/GAUL1/Country specific

• TargetGroup: Target group for vaccination. As a minimum the following should be reported: “ALL” for the overall figures, “HCW” for healthcare workers and age-groups (preferably using the detailed age-groups) ALL = Overall HCW = Healthcare workers LTCF = Residents in long term care facilities Age18_24 = 18-24 year-olds Age25_49 = 25-49 year-olds Age50_59 = 50-59 year-olds Age60_69 = 60-69 year-olds Age70_79 = 70-79 year-olds Age80+ = 80 years and over AgeUnk = Unknown age 1_Age<60 = below 60 years of age 1_Age60+ = 60 years and over

• Vaccine: Name of vaccine. Additional vaccines will be added on approval or as requested. COM = Comirnaty – Pfizer/BioNTech MOD = mRNA-1273 – Moderna CN = BBIBV-CorV – CNBG SIN = Coronavac – Sinovac SPU = Sputnik V - Gamaleya Research Institute AZ = AZD1222 – AstraZeneca UNK = UNKNOWN

• Population: Age-specific population for the country [Numeric]

##

Acknowledgements

European Centre for Disease Prevention and Control

As of July 21, 2022, most countries in the European Economic Area (EEA) had received the majority of their COVID-19 vaccine stock from Comirnaty (Pfizer/BioNTech). In Denmark, the Comirnaty vaccine accounted for 83 percent of the total COVID-19 vaccines distributed to the country. Hungary was the first country in the EEA to have received COVID-19 vaccines from Sinopharm and Sputnik V which were developed in China and Russia respectively. The current rate of COVID-19 vaccines administered in Europe can be found here. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

NOTE: As of 2/16/2023, this table is no longer being updated. For data on COVID-19 Updated (Bivalent) Booster Coverage by Age go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Age-/j2me-7k56. For information on COVID-19 vaccination primary series coverage for people less than 5 years go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccination-Primary-Series-Coverage-Age-L/su9q-qn6e Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages for state- and county-level tables (except coverage by CT SVI priority zip code). 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated, and addition dose 1 by age group. Age is based on age at the time of administration of the first dose. All data in this report are preliminary; data for previous dates will be updated as new reports are received, and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully

**Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool **

As of January 26, 2023, the population counts are based on Statistics Canada’s 2021 estimates. The coverage methodology has been revised to calculate age based on the current date and deceased individuals are no longer included. The method used to count daily dose administrations has changed is now based on the date delivered versus the day entered into the data system. Historical data has been updated.

Please note that Cases by Vaccination Status data will no longer be published as of June 30, 2022.

Please note that case rates by vaccination status and age group data will no longer be published as of July 13, 2022.

Please note that Hospitalization by Vaccination Status data will no longer be published as of June 30, 2022.

Learn more about COVID-19 vaccines.

Data includes:

• daily and total doses administered
• individuals with at least one dose
• individuals fully vaccinated
• total doses given to fully vaccinated individuals
• vaccinations by age
• percentage of age group
• individuals with at least one dose, by PHU, by age group
• individuals fully vaccinated, by PHU, by age group
• COVID-19 cases by status: not fully vaccinated, fully vaccinated, vaccinated with booster
• individuals in hospital due to COVID-19 (excluding ICU) by status: unvaccinated, partially vaccinated, fully vaccinated
• individuals in ICU due to COVID-19 by status: unvaccinated, partially vaccinated, fully vaccinated, unknown
• rate of COVID-19 cases per 100,000 by status and age group
• rate per 100,000 (7-day average) by status and age group

All data reflects totals from 8 p.m. the previous day.

This dataset is subject to change.

Additional notes

• Data entry of vaccination records is still in progress, therefore the dosage data may not be a full representation of all vaccination doses administered in Ontario.
• The data does not include dosage data where consent was not provided for vaccination records to be entered into the provincial CoVax system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information into CoVax.

Hospitalizations and cases by vaccination status

Hospitalizations

• This is a new data collection and the data quality will continue to improve as hospitals continue to submit data.
• In order to understand the vaccination status of patients currently hospitalized, a new data collection process was developed and this may cause discrepancies between other hospitalization numbers being collected using a different data collection process.
• Data on patients in ICU are being collected from two different data sources with different extraction times and public reporting cycles. The existing data source (Critical Care Information System, CCIS) does not have vaccination status.
• Historical data for hospitalizations by region may change over time as hospitals update previously entered data.
• Due to incomplete weekend and holiday reporting, vaccination status data for hospital and ICU admissions is not updated on Sundays, Mondays and the day after holidays
• Unvaccinated is defined as not having any dose, or between 0-13 days after administration of the first dose of a COVID-19 vaccine.
• Partially vaccinated is defined as 14 days or more after the first dose of a 2-dose series COVID-19 vaccine, or between 0-13 days after administration of the second dose
• Fully vaccinated is defined as 14 days or more after receipt of the second dose of a 2-dose series COVID-19 vaccine

Cases

• The cases by vaccination status may not match the daily COVID-19 case count because records with a missing or invalid health card number cannot be linked.

Weekly updates have finished. This dataset contains aggregate data by county for the age groups of individuals that received a COVID vaccination. Data includes counts of individuals who received a vaccine dose that provides partial coverage against the disease and counts of individuals that received a vaccine dose that provides full coverage against the disease. Age groups are presented in 5-year brackets. Suppression applies for quantities less than 5 and records under review.

Data only includes information reported to PA-SIIS, the Pennsylvania Statewide Immunization Information System.

Fully Vaccinated means that the person has received the necessary number of COVID-19 vaccines at the recommended time intervals.
First Booster Doses (Administered Since August 13, 2021)
First Booster doses administered since August 13, 2021 includes vaccinations beyond the primary series administered to the suggested groups at the recommended intervals on or after 08-13-2021 following CDC guidelines. Such vaccinations are commonly called booster doses. This category also includes additional does of COVID vaccine administered on or after 08-13-2021 to immunocompromised individual at the CDC recommended interval.

Second Booster Doses (Administered Since March 29, 2022)
Second booster doses administered since March 29, 2022 includes mRNA vaccinations beyond the primary series and one additional COVIDS vaccine as a second booster dose administered on or after 03-29-2022 to individuals ages 50+ at the recommended intervals per CDC guidelines. This category also includes additional doses of mRNA COVID vaccines administered on or after 03-29-2022 to immunocompromised individual at the CDC recommended internal.

Weekly updates have finished with the June 28th update. This dataset contains aggregate data by ethnicity for individuals that received a COVID vaccination. Data includes counts of individuals who received a vaccine dose that provides partial coverage against the disease and counts of individuals that received a vaccine dose that provides full coverage against the disease. Suppression applies for quantities less than 5.

Data only includes information reported to PA-SIIS, the Pennsylvania Statewide Immunization Information System.

Fully Vaccinated means that the person has received the necessary number of COVID-19 vaccines at the recommended time intervals.
First Booster Doses (Administered Since August 13, 2021)
First Booster doses administered since August 13, 2021 includes vaccinations beyond the primary series administered to the suggested groups at the recommended intervals on or after 08-13-2021 following CDC guidelines. Such vaccinations are commonly called booster doses. This category also includes additional does of COVID vaccine administered on or after 08-13-2021 to immunocompromised individual at the CDC recommended interval.

Second Booster Doses (Administered Since March 29, 2022)
Second booster doses administered since March 29, 2022 includes mRNA vaccinations beyond the primary series and one additional COVIDS vaccine as a second booster dose administered on or after 03-29-2022 to individuals ages 50+ at the recommended intervals per CDC guidelines. This category also includes additional doses of mRNA COVID vaccines administered on or after 03-29-2022 to immunocompromised individual at the CDC recommended internal.

As of 2022, the BioNTech vaccine against the coronavirus (COVID-19) was administered the most in Germany. Figures were significantly higher for BioNTech vaccinations, compared to the other vaccines approved for use in the EU – Moderna, AstraZeneca and Janssen. BioNTech is a German biotechnological company, which developed a vaccine against COVID-19 in cooperation with U.S. pharmaceutical giant Pfizer.

New vaccines BioNTech and Moderna are mRNA vaccines, AstraZeneca is not, but all three have one thing in common – they have to be administered in two doses over a period of several weeks to provide protection against the virus. The Janssen vaccine, also referred to as Johnson & Johnson, referring to its manufacturer, requires one dose. Both BioNTech and Moderna vaccines have already been administered as booster shots while another coronavirus wave engulfs Germany. After initial shortages in deliveries at the beginning of Germany’s vaccination campaign at the end of December 2020, production has ramped up, also within the country, and the German government repeatedly assures the population that there are enough vaccines for first, second and booster shots.

The next wave Thus far there is no national vaccination mandate in Germany, though heated debate among political parties regarding the issue continues, particularly in the wake of rising coronavirus cases in the winter of 2021 and the emergence of the Omicron variant. While all the currently greenlighted vaccines against COVID-19 are not said to make the recipient immune to the virus, they are widely hailed as helping reduce the risk of a difficult illness or the possibility of a hospital stay.

NOTE: As of 2/16/2023, this page is no longer being updated.

Important change as of June 1, 2022

As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages by gender at the state level. 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator.

• DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated grouped by gender and have additional dose 1 grouped by gender.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected.

Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used.

A person who has received at least one dose of any COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. Population estimates are based on 2019 CT population estimates. Bivalent booster administrations are not included in the additional dose 1 calculations.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional bivalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed.

The percent with at least one dose may be over-estimated and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. This includes doses given to residents of CT and to residents of other states vaccinated in CT. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records reported to CT WiZ. However, once CT residents who have received doses in each jurisdiction are added to CT WiZ, the records for residents of that jurisdiction vaccinated in CT are removed. For example, when CT residents vaccinated in NYC were added, NYC residents vaccinated in CT were removed.

Note: As part of continuous data quality improvement efforts, duplicate records

NOTE: This dataset has been retired and marked as historical-only. The recommended dataset to use in its place is https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Coverage-Citywide/6859-spec. COVID-19 vaccinations administered to Chicago residents based on the reported race-ethnicity and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). Vaccination Status Definitions: ·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine. ·People with a completed vaccine series: Number of people who have completed a primary COVID-19 vaccine series. Requirements vary depending on age and type of primary vaccine series received. ··People with an original booster dose: Number of people who have a completed vaccine series and have received at least one additional monovalent dose. This includes people who received a monovalent booster dose and immunocompromised people who received an additional primary dose of COVID-19 vaccine. Monovalent doses were created from the original strain of the virus that causes COVID-19. People with a bivalent dose: Number of people who received a bivalent (updated) dose of vaccine. Updated, bivalent doses became available in Fall 2022 and were created with the original strain of COVID-19 and newer Omicron variant strains. Weekly cumulative totals by vaccination status are shown for each combination of race-ethnicity and age group. Note that each age group has a row where race-ethnicity is "All" so care should be taken when summing rows. Vaccinations are counted based on the date on which they were administered. Weekly cumulative totals are reported from the week ending Saturday, December 19, 2020 onward (after December 15, when vaccines were first administered in Chicago) through the Saturday prior to the dataset being updated. Population counts are from the U.S. Census Bureau American Community Survey (ACS) 2019 1-year estimates. For some of the age groups by which COVID-19 vaccine has been authorized in the United States, race-ethnicity distributions were specifically reported in the ACS estimates. For others, race-ethnicity distributions were estimated by the Chicago Department of Public Health (CDPH) by weighting the available race-ethnicity distributions, using proportions of constituent age groups. Coverage percentages are calculated based on the cumulative number of people in each population subgroup (age group by race-ethnicity) who have each vaccination status as of the date, divided by the estimated number of Chicago residents in each subgroup. Actual counts may exceed population estimates and lead to >100% coverage, especially in small race-ethnicity subgroups of each age group. All coverage percentages are capped at 99%. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. CDPH uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Data reported in I-CARE only include doses administered in Illinois and some doses administered outside of Illinois reported historically by Illinois providers. Doses administered by the federal Bureau of Prisons and Department of Defense are also not currently reported in I-CARE. The Veterans Health Administration began reporting doses in I-CARE beginning September 2022. Due to people receiving vaccinations that are not recorded in I-CARE that c

A. SUMMARY This dataset represents the COVID-19 vaccinations given to residents of San Francisco. All vaccines given to SF residents are included, no matter where the vaccination took place (the vaccine may have been administered in San Francisco or outside of San Francisco). The data are broken down by multiple demographic stratifications. This dataset also includes COVID-19 vaccinations given to SF residents by the San Francisco Department of Public Health (SFDPH).

Data provides counts for residents who have received at least one dose, residents who have completed a primary vaccine series, residents who have received one or two monovalent (not bivalent) booster doses, and residents who have received a bivalent booster dose. A primary vaccine series is complete after an individual has received all intended doses of the initial series. There are one, two, and three dose primary vaccine series.

B. HOW THE DATASET IS CREATED Information on doses administered to those who live in San Francisco is from the California Immunization Registry (CAIR2), run by the California Department of Public Health (CDPH). The information on individuals’ city of residence, age, race, and ethnicity are also recorded in CAIR and are self-reported at the time of vaccine administration.

In order to estimate the percent of San Franciscans vaccinated, we provide the 2016-2020 American Community Survey (ACS) population estimates for each demographic group.

C. UPDATE PROCESS Updated daily via automated process

D. HOW TO USE THIS DATASET San Francisco population estimates for race/ethnicity and age groups can be found in a view based on the San Francisco Population and Demographic Census dataset. These population estimates are from the 2016-2020 5-year American Community Survey (ACS).

Before analysis, you must filter the dataset to the desired stratification of data using the "overall_segment" column.

For example, filtering "overall_segment" to "All SF Residents by Age Bracket, Administered by All Providers" will filter the data to residents whose vaccinations were administered by any provider. You can then further segment the data and calculate percentages by Age Brackets.

If you filter "overall_segment" to "All SF Residents by Race/Ethnicity, Administered by DPH Only", you will see the race/ethnicity breakdown for residents who received vaccinations from the San Francisco Department of Public Health (SFDPH).

If you filter "overall_segment" to "All SF Residents by Age Group, Administered by All Providers" you will see vaccination counts of various age eligibility groups that were administered by any provider.

To count the number of individuals vaccinated (with any primary series dose), use the "total_recipients" column. To count the number of individuals who have completed their primary vaccine series, use the "total_series_completed" column. To count the number of primary series doses administered (1st, 2nd, 3rd, or single doses), use the "total_primary_series_doses" column.

To count the number of individuals who received one or two monovalent (not bivalent) booster doses, use the "total_booster_recipients" and "total_2nd_booster_recipients" columns. To count the number of individuals who received their first bivalent booster dose, use the "total_bivalent_booster_recipients" column. To count the number of monovalent (not including bivalent) or bivalent booster doses administered, use the "total_booster_doses" or "total_bivalent_booster_doses" columns.

E. ARCHIVED DATA A previous version of this dataset was archived on 10/27/2022. For historical purposes, you can access the archived dataset at the following link:

ARCHIVED: COVID-19 Vaccine Doses Given to San Franciscans by Demographics

F. CHA